Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has been effective hard but unsuccessfully to produce a single therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in phrases of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be being used is actually an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as a combination treatment in the treatment of multi-drug-resistant HIV are actually closing.

I’m creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my last few shares. The 1st CytoDyn article of mine, “CytoDyn: What to be able to Do When It’s Too Good In order to Be True?”, set out what follows prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan presented such an extremely promotional picture in the Uptick Newswire interview which I came away with a poor viewpoint of the business.

Irony of irony, the bad viewpoint of mine of the business has grown steadily, however, the disappointment hasn’t been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger at the moment still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall relate to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your therapy as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti viral activity in HIV- infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of the expertise and linked intellectual property from Progenics to CytoDyn, as well as approximately 25 million mg of bulk drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 zillion) and the first new drug program approval ($5 million), and even royalty payments of five % of net sales upon commercialization.

Since that moment, CytoDyn’s guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to buy a market cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous indications and numerous therapies, it has this individual treatment as well as a “broad pipeline of indications” because it puts it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially advantageous therapy of dozens of indications.

The opening banner of its on its site (below) shows an energetic business with diverse interests albeit focused on leronlimab, multiple illness types, multiple publications and multiple delivering presentations.

Can all this be smoke cigarettes and mirrors? That’s a question I have been asking myself through the really beginning of the interest of mine in this company. Judging by way of the multiples of thousands of various commentary on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am far from alone in this question.

CytoDyn is a traditional battleground, or even some may say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label any bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *